Brain Hemorrhage – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Brain Hemorrhage – Pipeline Review, H2 2016’, provides an overview of the Brain Hemorrhage pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Brain Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Brain Hemorrhage and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Brain Hemorrhage

The report reviews pipeline therapeutics for Brain Hemorrhage by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Brain Hemorrhage therapeutics and enlists all their major and minor projects

The report assesses Brain Hemorrhage therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Brain Hemorrhage

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Brain Hemorrhage

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Brain Hemorrhage pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bio Products Laboratory Ltd

Edge Therapeutics Inc

F. Hoffmann-La Roche Ltd

Fina Biotech

MediPost Co Ltd

Pfizer Inc

Remedy Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Brain Hemorrhage Overview 6

Therapeutics Development 7

Pipeline Products for Brain Hemorrhage - Overview 7

Brain Hemorrhage - Therapeutics under Development by Companies 8

Brain Hemorrhage - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Brain Hemorrhage - Products under Development by Companies 12

Brain Hemorrhage - Companies Involved in Therapeutics Development 13

Bio Products Laboratory Ltd 13

Edge Therapeutics Inc 14

F. Hoffmann-La Roche Ltd 15

Fina Biotech 16

MediPost Co Ltd 17

Pfizer Inc 18

Remedy Pharmaceuticals Inc 19

Brain Hemorrhage - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

alteplase - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

aprotinin SR - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CN-105 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

glyburide - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

haptoglobin (human) - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

PF-05230907 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Pneumostem - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

PRC-14 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Recombinant Protein to Inhibit tPA and uPA for Intracranial Hemorrhage - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

RMP-HPE - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Stem Cell Therapy for Brain Stroke - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Brain Hemorrhage - Dormant Projects 45

Brain Hemorrhage - Discontinued Products 46

Brain Hemorrhage - Product Development Milestones 47

Featured News & Press Releases 47

Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of EG-1964 To Treat Brain Hemorrhage 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Number of Products under Development for Brain Hemorrhage, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Brain Hemorrhage – Pipeline by Bio Products Laboratory Ltd, H2 2016 13

Brain Hemorrhage – Pipeline by Edge Therapeutics Inc, H2 2016 14

Brain Hemorrhage – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 15

Brain Hemorrhage – Pipeline by Fina Biotech, H2 2016 16

Brain Hemorrhage – Pipeline by MediPost Co Ltd, H2 2016 17

Brain Hemorrhage – Pipeline by Pfizer Inc, H2 2016 18

Brain Hemorrhage – Pipeline by Remedy Pharmaceuticals Inc, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Brain Hemorrhage – Dormant Projects, H2 2016 45

Brain Hemorrhage – Discontinued Products, H2 2016 46

List of Figures

List of Figures

Number of Products under Development for Brain Hemorrhage, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports